Authors

Brooke McCormick

Brooke McCormick is an assistant editor for

Latest:

Dr Prerakkumar Parikh Reacts to FDA Approvals for First Neurology, Tocilizumab Biosimilars

Prerakkumar Parikh, PharmD, director of specialty clinical solutions at Magellan Rx Management, reacts to recent FDA approvals for the first natalizumab and tocilizumab biosimilars.

Gillian McGovern

Gillian is an assistant editor for Pharmacy Times®.

Latest:

House Committee Hearing Addresses PBMs, Anticompetitive Drug Pricing Tactics

The House Committee members examined pricing tactics by PBMs and how they are harming patients across the country.

Rose McNulty is a Managing Editor for

Latest:

Fresenius Kabi's Tocilizumab Biosimilar, Tyenne, Launches in US Market

Tyenne (tocilizumab-aazg) was the second tocilizumab biosimilar to be FDA approved, but it is the first to launch in the US.

Jessica Mourani, PharmD

Jessica Mourani, PharmD, is Director of Clinical Outcomes for CPS Solutions.

Latest:

Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?

Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.

Lindsey Mulrooney

Latest:

Julie Reed On How the Biosimilars Forum is Helping FDA Catch Up on Biosimilar Inspections

Julie M. Reed, the executive director of the Biosimilars Forum, dives into the efforts that the Forum is taking to ensure that FDA can catch up on their inspections backlog and get biosimilar approvals back on track.

Denise Myshko is your editorial contact for the Formulary Watch. She joined Formulary Watch as editor is June 2021 from Oncology Live. Prior to that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@mjhlifesciences.com

Latest:

CVS Caremark Switches Up Biosimilar Coverage in 2024

As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.

Kevin M. Nelson

Kevin M. Nelson is an intellectual property attorney

Latest:

IP Attorneys Propose a New Biosimilar Pathway in Case of ACA Repeal

Kathy Oubre, MS

Kathy W. Oubre, MS, is the Chief Operating Officer for Pontchartrain Cancer Center with locations in Covington and Hammond, Louisiana. In this role, she provides non-clinical leadership for all aspects of the practice, including financial counseling, policy/procedure development, revenue cycle management, advanced care planning, survivorship care and clinical trials.

Latest:

Biosimilars and Employers: Strategies for Success

The author, who is CEO of Pontchartrain Cancer Center, discusses how biosimilars can be part of a strategy for delivering high-quality care while achieving savings.

Joseph Park, PhD

Joseph Park, PhD, is the senior manager of regulatory strategy and policy at Samsung Bioepis. Park obtained his PhD from the Korea Advanced Institute of Science and Technology.

Latest:

Confusion Persists Around the Interchangeability Designation for Biosimilars

The legal and common uses of “interchangeability” continue to be conflated.

Justina Petrullo

Latest:

Dr Stephen Hanauer Gives Insight Into Growing US Adalimumab Market

Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, reflects on data concerning the potential for adalimumab biosimilars to gain significant market share.

Advertisement

Advertisement